Novo Nordisk To Slash US Insulin Prices, Following Move By Eli Lilly

Novo Nordisk said on Tuesday it would cut U.S. list prices for several insulin products by up to 75% next year, joining rival Eli Lilly and Co as political pressure mounts to make these life-sustaining diabetes treatments more affordable.